Kura Oncology, Inc.
$9.78
▲
3.24%
2026-04-21 07:47:01
kuraoncology.com
NMS: KURA
Explore Kura Oncology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$863.87 M
Current Price
$9.78
52W High / Low
$12.49 / $5.45
Stock P/E
—
Book Value
$1.98
Dividend Yield
—
ROCE
-48.86%
ROE
-94.82%
Face Value
—
EPS
$-3.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
260
Beta
0.24
Debt / Equity
11.75
Current Ratio
6.06
Quick Ratio
6.05
Forward P/E
-3.55
Price / Sales
11.35
Enterprise Value
$119.04 M
EV / EBITDA
-0.39
EV / Revenue
1.76
Rating
None
Target Price
$31.82
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arcus Biosciences, Inc. | $22.74 | — | $2.85 B | — | -42.51% | -63.26% | $26.4 / $7.06 | $5.04 |
| 2. | Lantern Pharma Inc. | $2.76 | — | $27.91 M | — | -275.14% | -1.24% | $5.74 / $1.11 | $0.58 |
| 3. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
| 4. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 5. | Immunovant, Inc. | $28.53 | — | $5.81 B | — | -61.93% | -69.35% | $29.48 / $13.36 | $4.85 |
| 6. | Indaptus Therapeutics, Inc. | $3.61 | — | $7.74 M | — | -629.32% | -5.88% | $19.91 / $1.51 | $1.45 |
| 7. | Rein Therapeutics Inc. | $1.83 | — | $51.31 M | — | -121.99% | -1.4% | $2.4 / $1.02 | $-1.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 17.34 M | 20.75 M | 15.29 M | 14.11 M | 53.88 M |
| Operating Profit | -86.27 M | -80 M | -72.67 M | -64.7 M | -22.45 M |
| Net Profit | -81 M | -74.12 M | -66.12 M | -57.43 M | -19.22 M |
| EPS in Rs | -0.92 | -0.84 | -0.75 | -0.65 | -0.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 67.48 M | 53.88 M | 0 M | 0 M |
| Operating Profit | -303.63 M | -193.19 M | -165.8 M | -139.87 M |
| Net Profit | -278.67 M | -173.98 M | -152.63 M | -135.84 M |
| EPS in Rs | -3.15 | -1.97 | -1.73 | -1.54 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 738.36 M | 760.16 M | 448.94 M | 456.31 M |
| Total Liabilities | 564.23 M | 346.52 M | 51.66 M | 36.03 M |
| Equity | 174.13 M | 413.64 M | 397.27 M | 420.28 M |
| Current Assets | 708.66 M | 744.83 M | 432.48 M | 446.43 M |
| Current Liabilities | 116.97 M | 78.71 M | 35.26 M | 24.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -64.06 M | 134.32 M | -124.82 M | -110.06 M |
| Investing CF | -13.1 M | -101.59 M | 15.56 M | 32.63 M |
| Financing CF | 1.79 M | 154.42 M | 94.78 M | 38.56 M |
| Free CF | -70.7 M | 133.84 M | -124.99 M | -110.69 M |
| Capex | -6.64 M | -0.47 M | -0.17 M | -0.63 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 25.24% | — | — | — |
| Earnings Growth % | -60.17% | -13.99% | -12.36% | — |
| Profit Margin % | -412.95% | -322.89% | — | — |
| Operating Margin % | -449.94% | -358.55% | — | — |
| Gross Margin % | 99.92% | 100% | — | — |
| EBITDA Margin % | -408.74% | -314.57% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.